Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure

被引:21
|
作者
Ogino, Kazuhide [1 ]
Kinugasa, Yoshiharu [2 ]
Kato, Masahiko [2 ]
Yamamoto, Kazuhiro [2 ]
Hisatome, Ichiro [3 ]
Anker, Stefan D. [4 ]
Doehner, Wolfram [5 ]
机构
[1] Tottori Univ Hosp, Div Clin Lab, Yonago, Tottori 6838504, Japan
[2] Tottori Univ, Fac Med, Dept Cardiovasc Med, Yonago, Tottori 683, Japan
[3] Tottori Univ, Grad Sch Med, Dept Genet Med & Regenerat Therapeut, Yonago, Tottori 683, Japan
[4] Charite, Campus Virchow Klinikum, Dept Cardiol, Div Appl Cachexia Res, D-13353 Berlin, Germany
[5] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany
关键词
Insulin resistance; Heart failure; Diabetes; Aldosterone; Inflammatory cytokine; Matrix metalloproteinase; ACUTE MYOCARDIAL-INFARCTION; NECROSIS-FACTOR-ALPHA; II RECEPTOR BLOCKER; PRIMARY ALDOSTERONISM; HYPERTENSIVE PATIENTS; HEPATIC STEATOSIS; OXIDATIVE STRESS; ADIPOSE-TISSUE; FOLLOW-UP; INFLAMMATION;
D O I
10.1016/j.ijcard.2013.12.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/objectives: Insulin resistance plays an important role in the pathophysiology in chronic heart failure (CHF). Diuretics generally have harmful effects on glucose metabolism, however, the effect of mineral corticoid receptor blockers on insulin resistance in CHF is unclear. This study aimed to evaluate the effects of the aldosterone blocker spironolactone, in comparison with furosemide, on insulin resistance in CHF patients. Methods: The effect of spironolactone (25 mg/day) and furosemide (20 mg/day) on IR for 16 weeks each was analyzed in 16 CHF patients using a double-blind, placebo-controlled, randomized cross-over study design. Results: Plasma BNP and left ventricular ejection fraction were improved with both treatments (furosemide: p = 0.02 and p = 0.009, respectively, spironolactone: p = 0.03 and p = 0.007, respectively). Fasting plasma glucose was not changed; however, plasma insulin levels decreased and insulin sensitivity (by homeostasis model assessment: HOMA-IR) improved with spironolactone as compared to furosemide (p < 0.0005). TNF-alpha, IL-6 and MCP-1 decreased with spironolactone (p = 0.002, p = 0.02 and p = 0.02 vs. baseline, respectively), but not with furosemide. Matrix metalloproteinase (MMP)-2 and MMP-9 were decreased with spironolactone (p = 0.003 and p = 0.04 vs. baseline, respectively), but not furosemide. Changes in TNF-a, IL-6 and MCP-1 levels after spironolactone treatment were significantly correlated with changes in HOMA-IR (r = 0.61, r = 0.55 and r = 0.65, respectively; p = 0.01, p = 0.03 and p = 0.01, respectively). Furthermore, changes in MMP-2 and MMP-9 levels were significantly correlated with changes in HOMA-IR (r = 0.58 and r = 0.58, respectively; p = 0.02 and p = 0.02, respectively). Conclusions: Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 50 条
  • [21] INSULIN-RESISTANCE IN CHRONIC HEART-FAILURE
    SWAN, JW
    WALTON, C
    GODSLAND, IF
    CLARK, AL
    COATS, AJS
    OLIVER, MF
    EUROPEAN HEART JOURNAL, 1994, 15 (11) : 1528 - 1532
  • [22] Predictors of insulin resistance in chronic systolic heart failure
    Voronkov, L.
    Ilnytska, M.
    Gavrilenko, T.
    Yakushko, L.
    Shkurat, I.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1054 - 1054
  • [23] Spironolactone improves coronary endothelial function in patients with chronic heart failure
    Saihara, K
    Hamasaki, S
    Yoshitama, T
    Ishida, S
    Yoshikawa, A
    Kataoka, T
    Orihara, K
    Oketani, N
    Fukudome, T
    Ogawa, M
    Okui, H
    Shinsato, T
    Minagoe, S
    Tei, C
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 519A - 519A
  • [24] Spironolactone Therapy in Heart Failure Patients with Chronic Kidney Disease Reply
    Lopes, Ricardo
    Lourenco, Patricia
    Mascarenhas, Joana
    Azevedo, Ana
    Bettencourt, Paulo
    CLINICAL CARDIOLOGY, 2009, 32 (10) : 597 - 597
  • [25] Clinical effects of combined treatment by optimal dose of furosemide and spironolactone on diastolic heart failure in elderly patients
    Chen, Zhi-Hao
    Jiang, Yu-Rong
    Peng, Jia-Qin
    Ding, Jia-Wang
    Li, Song
    Yang, Jian
    Wu, Hui
    Yang, Jun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 11 (03) : 890 - 894
  • [26] Spironolactone use in patients with heart failure
    Trujillo, JM
    Gonyeau, MJ
    DiVall, MV
    Alexander, SL
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (02) : 165 - 170
  • [27] Torasemide but not furosemide improves myocardial remodeling in patients with chronic heart failure
    López, B
    Sánchez, E
    González, A
    Querejeta, R
    Larman, M
    Querejeta, R
    Larman, M
    Díez, J
    CIRCULATION, 2003, 108 (17) : 342 - 342
  • [28] Renal Effects of Conivaptan, Furosemide, and the Combination in Patients With Chronic Heart Failure
    Goldsmith, Steven R.
    Gilbertson, David T.
    Mackedanz, Shari A.
    Swan, Suzanne K.
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (12) : 982 - 989
  • [29] EFFICACY AND SAFETY OF FUROSEMIDE AND A COMBINATION OF SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE IN CONGESTIVE HEART-FAILURE
    LEVY, B
    JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 17 (07): : 420 - 430
  • [30] Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil
    Saito, M
    Takada, M
    Hirooka, K
    Isobe, F
    Yasumura, Y
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2005, 30 (06) : 603 - 610